Table 1. Baseline Demographic and Disease Characteristics of Patientsa.
| Characteristic | Patients, No. (%) | |
|---|---|---|
| Dupilumab, 300 mg (n = 331) | Upadacitinib, 30 mg (n = 342) | |
| Sex | ||
| Male | 192 (58.0) | 183 (53.2) |
| Female | 139 (42.0) | 159 (46.5) |
| Age, mean (SD) [range], y | 36.3 (13.81) [18-76] | 36.2 (14.42) [18-76] |
| Age group, y | ||
| <40 | 223 (67.4) | 228 (66.7) |
| ≥40 to <65 | 94 (28.4) | 98 (28.7) |
| ≥65 | 14 (4.2) | 16 (4.7) |
| Disease duration since diagnosis, mean (SD), y | 25.5 (14.8) | 23.6 (14.8) |
| Weight, mean (SD), kg | 75.5 (18.6) | 78.8 (22.4) |
| BMI, mean (SD) | 25.97 (5.80) | 26.94 (6.53)b |
| BSA, mean (SD), % | 45.4 (22.7) | 48.7 (23.9) |
| vIGA-AD score | ||
| 3 (Moderate) | 159 (48.0) | 169 (49.4) |
| 4 (Severe) | 172 (52.0) | 173 (50.6) |
| EASI, mean (SD) | 29.2 (11.6) | 31.0 (12.6) |
| Worst Pruritus NRS [weekly average], mean (SD) | 7.5 (1.7) | 7.4 (1.6) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BSA, body surface area; EASI, Eczema Area and Severity Index; NRS, Numerical Rating Scale; vIGA-AD, validated Investigator’s Global Assessment.
a
Baseline demographic and disease characteristics assessed upon entry to Heads Up (study M16-046).
b
Data shown for 341 patients.